<code id='1093590B87'></code><style id='1093590B87'></style>
    • <acronym id='1093590B87'></acronym>
      <center id='1093590B87'><center id='1093590B87'><tfoot id='1093590B87'></tfoot></center><abbr id='1093590B87'><dir id='1093590B87'><tfoot id='1093590B87'></tfoot><noframes id='1093590B87'>

    • <optgroup id='1093590B87'><strike id='1093590B87'><sup id='1093590B87'></sup></strike><code id='1093590B87'></code></optgroup>
        1. <b id='1093590B87'><label id='1093590B87'><select id='1093590B87'><dt id='1093590B87'><span id='1093590B87'></span></dt></select></label></b><u id='1093590B87'></u>
          <i id='1093590B87'><strike id='1093590B87'><tt id='1093590B87'><pre id='1093590B87'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:knowledge    Page View:77649
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In